Bernard, Y., Ribeiro, N., Thuaud, F., Turkeri, G., Dirr, R., Boulberdaa, M., et al., 2011. Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27. PLoS One 6, e25302.
Blum, R.H., Carter, S.K., 1974. Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80, 249-259.
Bu'Lock, F.A., Gabriel, H.M., Oakhill, A., Mott, M.G., Martin, R.P., 1993. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 70, 185-188.
Cardinale, D., Bacchiani, G., Beggiato, M., Colombo, A., Cipolla, C.M., 2013. Strategies to prevent and treat cardiovascular risk in cancer patients. Semin Oncol 40, 186-198.
Childs, A.C., Phaneuf, S.L., Dirks, A.J., Phillips, T., Leeuwenburgh, C., 2002. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 62, 4592-4598.
Goldberg, S.J., Hutter, J.J., Jr., Feldman, L., Goldberg, S.M., 1983. Two sensitive echocardiographic techniques for detecting doxorubicin toxicity. Med Pediatr Oncol 11, 172-177.
Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Naga Prasad, S.V., et al., 2014. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124, 617-630.
Keizer, H.G., Pinedo, H.M., Schuurhuis, G.J., Joenje, H., 1990. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 47, 219-231.
Koh, E., Nakamura, T., Takahashi, H., 2004. Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 68, 163-167.
Krishnamurthy, B., Rani, N., Bharti, S., Golechha, M., Bhatia, J., Nag, T.C., et al., 2015. Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats. Chem Biol Interact 237, 96-103.
Lebrecht, D., Geist, A., Ketelsen, U.P., Haberstroh, J., Setzer, B., Walker, U.A., 2007. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol 151, 771-778.
Migrino, R.Q., Zhu, X., Pajewski, N., Brahmbhatt, T., Hoffmann, R., Zhao, M., 2007. Assessment of segmental myocardial viability using regional 2-dimensional strain echocardiography. J Am Soc Echocardiogr 20, 342-351.
Mohammadnejad, D., Abedelahi, A., Soleimani-Rad, J., Mohammadi-Roshandeh, A., Rashtbar, M., Azami, A., 2012. Degenerative effect of Cisplatin on testicular germinal epithelium. Adv Pharm Bull 2, 173-177.
Nagi, M.N., Mansour, M.A., 2000. Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res 41, 283-289.
Octavia, Y., Tocchetti, C.G., Gabrielson, K.L., Janssens, S., Crijns, H.J., Moens, A.L., 2012. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52, 1213-1225.
Razmaraii, N., Babaei, H., Mohajjel Nayebi, A., Asadnasab, G., Ashrafi Helan, J., Azarmi, Y., 2016a. Cardioprotective Effect of Phenytoin on Doxorubicin-induced Cardiac Toxicity in a Rat Model. J Cardiovasc Pharmacol 67, 237-245.
Razmaraii, N., Babaei, H., Mohajjel Nayebi, A., Assadnassab, G., Ashrafi Helan, J., Azarmi, Y., 2016b. Cardioprotective Effect of Grape Seed Extract on Chronic Doxorubicin-Induced Cardiac Toxicity in Wistar Rats. Adv Pharm Bull 6, 423-433.
Schwarz, E.R., Pollick, C., Dow, J., Patterson, M., Birnbaum, Y., Kloner, R.A., 1998. A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res 39, 216-223.
Shan, K., Lincoff, A.M., Young, J.B., 1996. Anthracycline-induced cardiotoxicity. Ann Intern Med 125, 47-58.
Takemura, G., Fujiwara, H., 2007. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49, 330-352.
Talas, Z.S., Ozdemir, I., Gok, Y., Ates, B., Yilmaz, I., 2010. Role of selenium compounds on tyrosine hydroxylase activity, adrenomedullin and total RNA levels in hearts of rats. Regul Pept 159, 137-141.
Tarr, A., Stoebe, S., Tuennemann, J., Baka, Z., Pfeiffer, D., Varga, A., et al., 2015. Early detection of cardiotoxicity by 2D and 3D deformation imaging in patients receiving chemotherapy. Echo Res Pract 2, 81-88.
Teraoka, K., Hirano, M., Yamaguchi, K., Yamashina, A., 2000. Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur J Heart Fail 2, 373-378.
Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., Schlattner, U., 2006. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41, 389-405.
Wouters, K.A., Kremer, L.C., Miller, T.L., Herman, E.H., Lipshultz, S.E., 2005. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 131, 561-578.